Beijing , China , October 20, 2008— Beijing Chemclin Biotech Co., Ltd. (“Chemclin”), a leading company in diagnostics reagents and systems in China, today announced that it has completed its Series B financing. This $16.5 million funding was led by China Healthcare Partnership (managed by MC China) with participation of existing investors, WI Harper, Siemens Venture Capital, and SB China Venture Capital.

China eCapital served as the exclusive financial advisor to Chemclin in the transaction.

“We are very pleased to add China Healthcare Partnership as our new investor in Chemclin,” said Mr. Xitang Ying, CEO of Chemclin. “The international healthcare management experience and great support of these top tier investors will undoubtedly strengthen our position to become a leader in China’s diagnostic market and be of great assistance as we build a global diagnostics company,” he added.

This is the first private equity investment of the newly launched China Healthcare Partnership, which is a partnership managed by MC China, a Martin Currie Group company. “Of the many healthcare-related companies we’ve looked at, this is one of the rare ones that meets our quality requirements,” said Vicky Yun Chen, a Partner at China Healthcare Partnership. “In addition to its broad diagnostics product offerings, the company has a solid technology background and has built an extensive distribution network for its large product/reagents offering in Chemiluminescence Immunoassays (CLIA) diagnostics, an in-vitro diagnostic method that is more advanced than the commonly used Enzyme-Linked ImmunoSorbent Assay (ELISA) in China. Chemclin was the first company in China to launch a full panel of chemiluminesence diagnostics for blood borne diseases, including the acquired immunodeficiency syndrome (AIDS), syphilis, hepatitis C, and hepatitis B, and also carries a breadth of tumor diagnostic panels. Chemclin’s products have gained wide acceptance and high recognition by the Chinese healthcare community. Most importantly, the company has a credible and capable management team that is essential in building a successful company with sustainable growth in China. We are very pleased to be joining fellow investors WI Harper, Siemens Venture Capital and SB Venture Capital in this exciting time in Chemclin’s development.”

Commenting on this transaction, Irene Tanner, China eCapital’s partner in charge of its healthcare group, said “It is a gratifying experience to see the transaction closed at such an extraordinarily difficult time in the global capital markets. Helping Chemclin in both its A round and B round is testimonial to our philosophy of building long-term relationships with clients that have the potential to become market leaders.”

About China eCapital